Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in children with moderate-to-severe inadequately controlled allergic asthma
2015-003538-28Phase 3
- Sponsor
- Novartis
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic asthma comparing Omalizumab with Placebo (2 arms). Primary endpoint: Rate of clinically significant asthma exacerbations per patient in the 24-week fixed-dose steroid treatment period.
02
Drugs
omalizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on 2015-003538-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003538-28.